Memantine ER/Donepezil: A Review in Alzheimer's Disease (Q38401091)

2 September 2017

title

Memantine ER/Donepezil: A Review in Alzheimer's Disease (English)

1 reference

2 September 2017

0 references

Sarah L Greig

1

1 reference

2 September 2017

publication date

30 October 2015

1 reference

2 September 2017

1 reference

2 September 2017

volume

29

1 reference

2 September 2017

issue

11

1 reference

2 September 2017

page(s)

963-970

1 reference

2014 Alzheimer's disease facts and figures

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0287-2

Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0287-2

Donepezil and memantine for moderate-to-severe Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0287-2

EFNS-ENS/EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0287-2

Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0287-2

Long-term course and effectiveness of combination therapy in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0287-2

Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0287-2

Memantine extended release (28 mg once daily): a review of its use in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0287-2

Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0287-2

A novel once-daily fixed-dose combination of memantine extended release and donepezil for the treatment of moderate to severe Alzheimer's disease: two phase I studies in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0287-2

The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer's disease taking cholinesterase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0287-2

Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer's dementia: a pooled area under the curve analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0287-2

Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0287-2

Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0287-2

Predictors of adherence among Alzheimer's disease patients receiving oral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0287-2

A population-based study of dosing and persistence with anti-dementia medications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0287-2

Cost-utility analysis of memantine extended release added to cholinesterase inhibitors compared to cholinesterase inhibitor monotherapy for the treatment of moderate-to-severe dementia of the Alzheimer's type in the US.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0287-2

Effective pharmacological management of Alzheimer's disease.

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26519339

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S40263-015-0287-2

1 reference

2 September 2017

1 reference